ATNM
Actinium Pharmaceuticals, Inc.Company Information
- Company Name
- Actinium Pharmaceuticals, Inc.
- CIK
- CIK0001388320
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ATNM: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ATNM
SEC filing data through
Insider Sentiment
- Last purchase
- 2018-12-10
- Last sale
- 2016-08-31
- Shares purchased (TTM)
- 79,730
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 4,657,661
- Shares outstanding
- 31,237,681
- Ownership
- 14.91%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 26.73%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 36 | 42 | 48 | 53 | 60 | 65 | 73 | 79 | 86 | 84 | 77 | 83 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 3 | ||||||
| Assets Current | 38 | 43 | 49 | 54 | 61 | 66 | 75 | 80 | 87 | 85 | 78 | 86 | ||||||
| Property Plant And Equipment Net | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 40 | 45 | 52 | 56 | 63 | 69 | 77 | 82 | 90 | 88 | 81 | 89 | ||||||
Liabilities Current | ||||||||||||||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | 8 | 8 | 8 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 9 | 7 | 7 | 6 | 8 | 7 | 8 | 7 | 9 | - | 8 | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 9 | 7 | 8 | 7 | 8 | 7 | 8 | 8 | 10 | 8 | 8 | 9 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | 35 | 35 | 35 | ||||||
| Contract With Customer Liability Noncurrent | - | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | - | 35 | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities | 10 | 43 | 44 | 42 | 44 | 43 | 44 | 44 | 46 | 44 | 45 | 45 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 418 | 418 | 418 | 418 | 418 | 417 | 409 | 407 | 401 | 390 | 374 | 372 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | - | - | - | - | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -387 | -415 | -410 | -404 | -399 | -392 | -376 | -369 | -358 | -346 | -338 | -328 | ||||||
| Stockholders Equity | 30 | 2 | 8 | 14 | 19 | 26 | 33 | 38 | 44 | 44 | 36 | 44 | ||||||
| Liabilities And Stockholders Equity | 40 | 45 | 52 | 56 | 63 | 69 | 77 | 82 | 90 | 88 | 81 | 89 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||||||
| Common Stock Shares Issued | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 29 | 28 | 27 | ||||||
| Shares Outstanding | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 29 | 28 | 27 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialActinium Pharmaceuticals, Inc. (ATNM) — SEC Financial Statements & Analysis
Actinium Pharmaceuticals, Inc. (ATNM) is a pharmaceutical preparations company, incorporated in DE. Actinium Pharmaceuticals, Inc. trades on NYSE as: ATNM. Actinium Pharmaceuticals, Inc. (ATNM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, Actinium Pharmaceuticals, Inc. carries a market cap of $30.77M, a P/E ratio of 2.72x, a P/B ratio of 1.02x, a P/S ratio of 0.88x, an enterprise value of $-6.04M, and an EV/EBITDA multiple of -0.62x. On profitability, it posts an operating margin of 27.23%, a net margin of 32.23%, a Return on Equity (ROE) of 45.86%, and a Return on Assets (ROA) of 21.92%. Per share, it reports EPS of $0.36, diluted EPS of $0.36, free cash flow per share of $-0.74, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -127.56% year-over-year, and EPS growth of -127.38% year-over-year. On the balance sheet, it maintains a current ratio of 4.08x, a quick ratio of 3.94x, working capital of $28.48M, a debt-to-equity ratio of 0.33x, a debt ratio of 0.25, an interest coverage ratio of -45.44x, free cash flow of $-23.14M (TTM), and net debt of $-36.81M. Figures sourced from SEC EDGAR.
- Market Cap
- $30.77M
- P/E TTM
- 2.72x
- EPS TTM
- $0.36
- P/B TTM
- 1.02x
- ROE TTM
- 45.86%
- ROA TTM
- 21.92%
- Debt To Equity
- 0.33x
- Free Cash Flow TTM
- $-23.14M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Actinium Pharmaceuticals, Inc. in?
Actinium Pharmaceuticals, Inc. (ATNM) operates in the Pharmaceutical Preparations industry.
What exchange does ATNM trade on?
Actinium Pharmaceuticals, Inc. (ATNM) trades on the NYSE.
Where is Actinium Pharmaceuticals, Inc. incorporated?
Actinium Pharmaceuticals, Inc. is incorporated in DE.
When was Actinium Pharmaceuticals, Inc. (ATNM)'s most recent SEC filing?
Actinium Pharmaceuticals, Inc. (ATNM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is ATNM's market cap?
Actinium Pharmaceuticals, Inc. (ATNM) has a market capitalization of $30.77M as of 2026-06-30.
What is ATNM's P/E ratio?
Actinium Pharmaceuticals, Inc. (ATNM)'s trailing twelve month P/E ratio is 2.72x as of 2026-06-30.
What is ATNM's EPS (earnings per share)?
Actinium Pharmaceuticals, Inc. (ATNM)'s trailing twelve month EPS is $0.36 as of 2026-06-30.
What is ATNM's ROE (return on equity)?
Actinium Pharmaceuticals, Inc. (ATNM)'s trailing twelve month Return on Equity (ROE) is 45.86% as of 2026-06-30.
What is ATNM's ROA (return on assets)?
Actinium Pharmaceuticals, Inc. (ATNM)'s trailing twelve month Return on Assets (ROA) is 21.92% as of 2026-06-30.
What is ATNM's EV/EBITDA?
Actinium Pharmaceuticals, Inc. (ATNM)'s trailing twelve month EV/EBITDA is -0.62x as of 2026-06-30.